DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Thibaut Mongon - 1 Paul Ruh - 1 Johnson - 1 J - 1 Joseph Wolk - 1 Wolk - 1 J's - 1 CNBC's - 1
Top related locs:
New York City U.S
Top related orgs:
Kenvue Inc - 1 New York Stock Exchange - 1 JPMorgan - 1

Search resuls for: "Paul Ruh"


3 mentions found


☆ Johnson & Johnson investors can soon swap their shares for Kenvue stock — here's what you need to know
  + stars: | 2023-07-20 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Johnson & Johnson on Thursday said its shareholders will soon be able to swap their shares for stock of Kenvue , which spun out as an independent consumer health company just two months ago. That process, also known as a split-off, will allow J&J shareholders to exchange all or a portion of their shares for Kenvue's common stock. Kenvue shares fell following the announcement Thursday, even though the company beat earnings and revenue estimates in its first quarterly report since its IPO. Previously, J&J did not disclose whether it would divest its Kenvue shares through a split-off or a spinoff. The latter would involve distributing Kenvue stock to existing J&J shareholders rather than giving them the option to exchange.
Persons: Thibaut Mongon, Paul Ruh, Johnson, J, Joseph Wolk, Wolk, J's, CNBC's, Kenvue, Goldman Sachs, JPMorgan Chase Organizations: Kenvue Inc, New York Stock Exchange, JPMorgan Locations: New York City, U.S
☆ J&J's consumer health spinoff Kenvue opens at $25.53, a 16% jump, in public market debut
  + stars: | 2023-05-04 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +1 min
Thibaut Mongon, CEO and Paul Ruh CFO of Kenvue Inc. a Johnson & Johnson's consumer-health business, pose together during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023. Johnson & Johnson 's consumer health spinoff Kenvue jumped 16% in its market debut on the New York Stock Exchange Thursday, marking the biggest U.S. IPO in more than a year. Kenvue sold 172.8 million shares in an upsized deal that raised about $3.8 billion and valued the company at roughly $41 billion. "Millions of consumers around the world this morning wake up with a Kenvue product in their home," CEO Thibaut Mongon, told CNBC's "Squawk on the Street" Thursday morning ahead of the stock's debut. Mongon previously served as J&J's executive vice president and worldwide chair of consumer health.
☆ Johnson & Johnson to price shares of consumer spinoff Kenvue at $20 to $23 in IPO
  + stars: | 2023-04-24 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Johnson & Johnson will price shares of its consumer-health spinoff Kenvue at $20 to $23 in an initial public offering later this year, the company said in a regulatory filing Monday. J&J said it launched a roadshow for the IPO of more than 151 million shares of common stock. Kenvue estimates the IPO will generate net proceeds of around $3.15 million, the filing said. Kenvue expects to grant underwriters a 30-day option to purchase up to an additional 22.6 million shares of stock to cover any over-allotments, according to the filing. The company noted it will own 1.7 billion shares of Kenvue's common stock after the IPO, representing 91.9% of the spinoff's total shares.
0 next >>
Total: 3